#National Institute of Allergy and Infectious Diseases

HVAD 2023 honors the many individuals advancing HIV vaccine research.

NIAID-supported research sheds light on why healthy people of the same age respond differently to vaccines.

Fauci, who has directed the National Institute of Allergy and Infectious Diseases since 1984, will step down in December.

The NIH and local researchers are collaborating to evaluate the antiviral drug TPOXX.

The small study found no evidence of delayed development of antibodies in participants who experienced rebound after taking Paxlovid.

The study, sponsored by the National Institutes of Health, will gather data on tecovirimat, or TPOXX.

Higher levels of viral antigens in the blood correlated with more severe disease.

Fauci led the U.S. HIV research effort for nearly 40 years before becoming the nation’s leading COVID-19 medical advisor.

What have we learned from the COVID-19 pandemic, and what’s the future of HIV vaccine research? Find out this #HVAD2022.

The HVTN 302 trial is evaluating experimental vaccines that deliver stabilized HIV spike proteins.

The experimental vaccine regimen aims to train B cells to produce broadly neutralizing antibodies against HIV.

New vaccine approach triggers neutralizing antibody production and T-cell responses and lowers risk of infection.

The removal of “AIDS” from the names of two CDC HIV agencies coincides with structural changes.

The National Institutes of Health awarded grants for HIV cure research to these 10 organizations. One focuses on pediatric populations.

AVAC’s theme for HVAD 2021 is “HIV Vaccine Research: Building on Lessons from COVID.”